[{"from": "human", "value": "Describe this molecule. [C][C][/C][=Branch2][Ring2][C][=C][Branch2][Ring1][Ring1][/C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][O][C][C][N][Branch1][C][C][C][\\C][=C][C][=Branch1][=Branch1][=C][C][=C][Ring1][=Branch1][O][/C][=C][C][=C][C][=C][Ring1][=Branch1]"}, {"from": "gpt", "value": "The molecule is a novel selective estrogen receptor modulator (SERM). Droloxifene also exhibits more rapid pharmacokinetics, reaching peak concentrations and being eliminated much more rapidly than tamoxifen. Its higher affinity to the estrogen receptor, higher anti-estrogenic to estrogenic ratio, more effective inhibition of cell growth and division in estrogen receptor-positive cell lines, and lower toxicity give it theoretical advantages over tamoxifen in the treatment of human breast cancer. Short-term toxicity was generally mild, and similar to that seen with other antiestrogens. Droloxifene appears active and tolerable. It may have a particular role in situations in which rapid pharmacokinetics, or an increased antiestrogenic to estrogenic ratio, are required. Droloxifene may also be a potentially useful agent for the treatment of postmenopausal osteoporosis because it can prevent estrogen deficiency-induced bone loss without causing uterine hypertrophy. Droloxifene may have an effect on bone and breast tissue because it induces apoptosis. Droloxifene has an anti-implantation effect in rats, and the effect appears to be not completely due to its anti-estrogenic activity."}]